Day: November 29, 2022

HeadlinesDelivered strong full fiscal new bookings at $684M, up 16% year over year Record fiscal year revenue for Professional Services Awarded strategic win-back program from big tech Cerence technology in 51% of global auto productionBURLINGTON, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its fourth quarter and fiscal year 2022 results for the year ended September 30, 2022. Results Summary (1) (in millions, except per share data)    Three Months Ended     Twelve Months Ended      September 30,     September 30,      2022     2021     2022     2021  GAAP revenue     $58.1       $98.1       $327.9       $387.2  GAAP gross margin       58.1 %       75.4 %       70.4 %       73.9 %Non-GAAP gross margin       58.9 %       78.1 %       72.4 %       77.3 %GAAP...

NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.    The Annual Meeting of Stockholders and webcast can be accessed via www.virtualshareholdermeeting.com/GALT2022. Please log in approximately 10 minutes before the event to ensure a timely connection. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based...

DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz. A copy of the poster will be made available on the Zynerba corporate website following the presentation at www.zynerba.com/publications.Poster Presentation Details   Title: An Open-Label Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)   Date available: Available online beginning December 5, 2022 for entirety of conference   Live...

While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in Just 90 Days, Wholesale Prices Remain Low Due to Excess Supply and Other Industry Factors VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF), a growth-oriented and diversified company focused on the international cannabis industry, announces that the Propagation Services Canada Inc. joint venture of which it owns 70%, which is currently doing business as “Boundary Bay Cannabis” (“BBC” or the “Joint Venture”), has received approximately $910,000 worth of purchase orders for its cannabis since August 31, 2022. The purchase orders were received from multiple parties and represent a total of over 725,000 grams of processed product. BBC’s strategy continues...

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world. Under the terms of the agreement,...

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior Studies Bemnifosbuvir’s Unique Mechanism with Dual Targets Creates a Higher Barrier to Resistance and Retains Antiviral Activity Against COVID-19 Variants BOSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the SUNRISE-3 Phase 3 trial, a global multicenter trial evaluating bemnifosbuvir (AT-527) for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression to hospitalization and death....

MAGNA TO TAKE CES 2023 BY STORM WITH LATEST TECH FOR A BETTER WORLD OF MOBILITY Magna’s booth at CESMagna to display future-ready solutions at CES 2023 Mobility tech company will flex the ‘Power of Magna’ across four areas of complete vehicle and systems expertise Interactive exhibit is located in the West Hall of the Las Vegas Convention Center, booth #4425AURORA, Ontario, Nov. 29, 2022 (GLOBE NEWSWIRE) — Magna is gearing up among the world’s leading innovators at CES 2023 in Las Vegas, where it will illustrate its world-class mobility solutions for a safer, more sustainable future for all. The company will highlight its latest technologies in the areas of eco-innovation, driver assistance, distinction and experience, and new mobility – reinforcing how the company’s complete vehicle and systems expertise enables it...

GREENWICH, Conn. , Nov. 29, 2022 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of less-than-truckload transportation in North America, has announced that its third annual Soles4Souls shoe drive is underway and will run through December 31. Soles4Souls turns shoes and clothing into opportunities for people around the world.  XPO has designated 142 of its largest US sites to serve as collection points for new or gently used shoes donated by employees and the public. The company will transport the shoes to Soles4Souls for distribution, and has pledged a cash donation for each pair of shoes collected. LaQuenta Jacobs, XPO’s chief diversity officer and Soles4Souls board member, said, “We launched our shoe drive on Giving Tuesday to call attention to the importance of collective acts of kindness. Soles4Souls has set a goal of...

WINNEMUCCA, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that the Federal Bureau of Land Management (“BLM”) has accepted the Plan of Operations (the “Plan”) for the proposed high-grade underground Grassy Mountain gold mine in eastern Oregon as complete. With completeness, the BLM will issue a Notice of Intent thereby initiating the Environmental Impact Statement (“EIS”) process under the National Environmental Policy Act (“NEPA”). The EIS is a comprehensive analysis of the impact of the proposed mine on the environment. The EIS culminates in the Record of Decision that sets out the BLM’s decision regarding the proposed mining operations. Glen Van Treek, the Company’s President and COO, stated, “Our ongoing collaboration with the BLM...

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the “Board”) effective November 29, 2022. With more than 30 years of biopharmaceutical industry knowledge, Mr. Garland brings deep commercial and executive leadership experience. “Scott is a biopharmaceutical industry leader who brings broad commercial, portfolio management, and leadership experience to the Board,” said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology. “His strategic expertise and counsel will be critical to ALX as we continue to expand the potential value of evorpacept as a cornerstone therapy for the treatment...